Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sildenafil Citrate

FDA-approved product (tablet, oral), marketed as Liqrev, Revatio, Sildenafil Citrate and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Sildenafil Citrate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Connective tissue disease
  • Erectile dysfunction
  • Idiopathic and/or familial pulmonary arterial hypertension
  • Impotence
  • Pulmonary arterial hypertension
  • Pulmonary hypertension

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Drugs used in erectile dysfunction
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae39.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sildenafil Citrate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sildenafil Citrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Blood Pressure Interaction Between Sildenafil and Sublingual Glyceryl Trinitrate (GTN) in Men With Angina

    NCT00479908 · start 2004-01

    Registered record
    Registry ID
    NCT00479908
    Conditions
    Angina Pectoris
    Interventions
    Sildenafil citrate; Glyceryl trinitrate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-01
    Completion
    2005-09
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAngina Pectoris
    InterventionSildenafil citrate; Glyceryl trinitrate
    PhasePhase 4
    Registry statusCompleted

  • A Multicenter, Double-blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Sildenafil on the As-Needed Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 Diabetes

    NCT00645268 · start 2002-12

    Registered record
    Registry ID
    NCT00645268
    Conditions
    Erectile Dysfunction; Diabetes Mellitus, Type 2
    Interventions
    sildenafil; placebo; sildenafil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-12
    Completion
    2004-01
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction; Diabetes Mellitus, Type 2
    Interventionsildenafil; placebo; sildenafil
    PhasePhase 4
    Registry statusCompleted

  • Efficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary Pulmonary Hypertension

    NCT00155714 · start 2002-11

    Registered record
    Registry ID
    NCT00155714
    Conditions
    Primary and Secondary Pulmonary Hypertension
    Interventions
    type-5 phosphodiesterase Inhibitor (Sildenafil)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2002-11
    Completion
    2005-05
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary and Secondary Pulmonary Hypertension
    Interventiontype-5 phosphodiesterase Inhibitor (Sildenafil)
    PhaseNot applicable
    Registry statusWithdrawn

  • A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension

    NCT00644605 · start 2002-10

    Registered record
    Registry ID
    NCT00644605
    Conditions
    Hypertension, Pulmonary
    Interventions
    sildenafil; sildenafil; placebo; sildenafil
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-10
    Completion
    2003-11
    Enrolment
    275

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension, Pulmonary
    Interventionsildenafil; sildenafil; placebo; sildenafil
    PhasePhase 3
    Registry statusCompleted

  • A Study Evaluating the Efficacy and Safety of Sildenafil in Patients With Erectile Dysfunction Receiving Hemodialysis

    NCT00654017 · start 2002-10

    Registered record
    Registry ID
    NCT00654017
    Conditions
    Erectile Disfunction; Hemodialysis
    Interventions
    placebo; sildenafil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-10
    Completion
    2005-04
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Disfunction; Hemodialysis
    Interventionplacebo; sildenafil
    PhasePhase 4
    Registry statusCompleted